A study reported in the American Journal of Psychiatry reported on whether clonidine blocks stress-induced seeking of heroin and cocaine. This study was not performed in the Clinical Trials Network, but involved a researcher from the Center for the Clinical Trials Network and is relevant to the CTNs Opioid Research Task Force.
To find out if clonidine might work in that role, researchers conducted a randomized, double-blind, placebo-controlled clinical trial with 208 opioid-dependent patients at an outpatient buprenorphine clinic.
The 118 participants (57%) who achieved abstinence during weeks 5-6 were continued on buprenorphine and randomly assigned to receive clonidine (n=61) or placebo (n=57) for 14 weeks. Urine was tested three times per week, with "lapse" defined as any opioid-positive or missed urine test, and "relapse" defined as two or more consecutive lapses.
Analysis found that clonidine produced the longest duration (in consecutive days) of abstinence from opioids during the intervention phase. There was no difference between clonidine and placebo groups in time to relapse, but those in the clonidine group took longer to lapse. Assessment showed that the impact of daily life stress on opioid craving was partly mitigated in the clonidine group.
Conclusions: Clonidine, a readily available medication, is useful in opioid dependence treatment not just for reduction of withdrawal signs, but also as an added maintenance treatment that increases duration of abstinence. Even in the absence of physical withdrawal, it appears to help decouple stress from craving in everyday life, making it a potentially valuable tool in maintaining abstinence for those in recovery.